Analysis & Commentary: The urgency of providing comprehensive and integrated treatment for substance abusers with HIV

Health Affairs

Volumn 30, Issue 8, 2011, Pages 1411-1419

  Volkow, Nora D ^a   Montaner, Julio ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

ARTICLE; CLINICAL PRACTICE; HARM REDUCTION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PUBLIC HEALTH; SUBSTANCE ABUSE; VIRUS TRANSMISSION; ADDICTION; INTEGRATED HEALTH CARE SYSTEM; TREATMENT OUTCOME;

DELIVERY OF HEALTH CARE, INTEGRATED; HIV INFECTIONS; HUMANS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84855176066     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.0663     Document Type: Article

References (71)

1. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-9.
2. Ostrow DG, Plankey MW, Cox C, Li X, Shoptaw S, Jacobson LP, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009;51(3):349-55.
3. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53(5):619-24.
4. Santos GM, Das M, Colfax GN. Interventions for non-injection substance use among US men who have sex with men: what is needed. AIDS Behav. 2011;15(Suppl 1):S51-6.
5. Abdala N, White E, Toussova OV, Krasnoselskikh TV, Verevochkin S, Kozlov AP, et al. Comparing sexual risks and patterns of alcohol and drug use between injection drug users (IDUs) and non-IDUs who report sexual partnerships with IDUs in St. Petersburg, Russia. BMC Public Health. 2010;10:676.
6. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793-800.
7. National Institute on Drug Abuse [Internet]. Bethesda (MD): NIDA. Press release, Unprecedented effort to seek, test, and treat inmates with HIV; 2010 Sep 23 [cited 2011 Jul 29]. Available from: http://www .nida.nih.gov/newsroom/10/ NR9-23.html
8. Fenton KA, Mermin JH. e-HAP Direct: Dear Colleague letter [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2011 May 13 [cited 2011 Jul 20]. Available from: http://www.cdc.gov/hiv/ ehap/resources/direct/05132011/ discordant.htm
9. National Institute of Allergy and Infectious Diseases [Internet]. Bethesda (MD): NIAID. Press release, Treating HIV-infected people with antiretrovirals protects partners from infection; 2011 May 12 [cited 2011 Jul 20]. Available from: http://www.niaid.nih.gov/news/ newsreleases/2011/Pages/ HPTN052.aspx
10. Kirk G, Galai N, Astemborski J, Linas B, Celentano D, Mehta S, et al. Decline in community viral load is strongly associated with declining HIV incidence among IDUs. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27-Mar 2; Boston, MA. (Abstract No. 484).
11. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
12. Menza TW, Jameson DR, Hughes JP, Colfax GN, Shoptaw S, Golden MR. Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial. BMC Public Health. 2010;10:774.
13. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/ naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1): S22-32.
14. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011; 113(2-3):192-9.
15. Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F. Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):S10-6.
16. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651): 1733-45.
17. Van Tieu H, Koblin BA. HIV, alcohol, and noninjection drug use. Curr Opin HIV AIDS. 2009;4(4):314-8.
18. Degenhardt L, Mathers B, Guarinieri M, Panda S, Phillips B, Strathdee SA, et al. Meth/amphetamine use and associated HIV: implications for global policy and public health. Int J Drug Policy. 2010;21(5):347-58.
19. Colfax G, Santos GM, Chu P, Vittinghoff E, Pluddemann A, Kumar S, et al. Amphetamine-group substances and HIV. Lancet. 2010; 376(9739):458-74.
20. Rossi D, Radulich G, Muzzio E, Naveira J, Sosa-Estani S, Rey J, et al. Multiple infections and associated risk factors among non-injecting cocaine users in Argentina. Cad Saude Publica. 2008;24(5):965-74.
21. Comprehensive approaches to HIV prevention for people who use drugs. Chap. 3 in: Meeting report: Prevention and treatment of HIV/ AIDS among drug using populations: a global perspective. Washington (DC): Internal Aids Society and National Institute on Drug Abuse; 2010. p. 19-35.
22. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50(1):93-9.
23. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc. 2004;10(1):1-14.
24. Langford D, Adame A, Grigorian A, Grant L, McCutchan JA, Ellis RJ, et al. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr. 2003;34(5):467-74.
25. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US states, 1996-2004. PLoS One. 2009;4(2): e4445.
26. Romeo R, Rumi MG, Donato MF, Cargnel MA, Viganò P, Mondelli M, et al. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. J Viral Hepat. 2000;7(4):297-301.
27. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;113 (Suppl 1):97-106.
28. Farrell M, Gowing L, Marsden J, Ling W, Ali R. Effectiveness of drug dependence treatment in HIV prevention. Int J Drug Policy. 2005;16S: S67-75.
29. Schroeder JR, Epstein DH, Umbricht A, Preston KL. Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav. 2006;31(5):868-79.
30. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907-13.
31. Woody GE, Gallop R, Luborsky L, Blaine J, Frank A, Salloum IM, et al. HIV risk reduction in the National Institute on Drug Abuse Cocaine Collaborative Treatment Study. J Acquir Immune Defic Syndr. 2003; 33(1):82-7.
32. Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5): 550-4.
33. Volkow N, Montaner J. Enhanced HIV testing, comprehensive treatment, and support for HIV-infected substance users-an essential component of a successful HIV/AIDS control strategy. JAMA. 2010; 303(14):1423-4.
34. Donoghoe MC, Bollerup AR, Lazarus JV, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004. Int J Drug Policy. 2007; 18(4):271-80.
35. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103(8):1242-57.
36. Metzger DS, Woody GE, O'Brien CP. Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr. 2010;55(Suppl 1): S32-6.
37. Werb D, Mills EJ, Montaner JS, Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis. 2010;10(7):464-9.
38. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users. AIDS. 2005; 19(8):837-9.
39. Wood E, Hogg RS, Yip B, Dong WW, Wynhoven B, Mo T, et al. Rates of antiretroviral resistance among HIVinfected patients with and without a history of injection drug use. AIDS. 2005;19(11):1189-95.
40. Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis. 2010;50(1):98-105.
41. Robison LS, Westfall AO, Mugavero MJ, Kempf MC, Cole SR, Allison JJ, et al. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses. 2008; 24(11):1347-55.
42. Brown L, Kritz SA, Goldsmith RJ, Bini EJ, Rotrosen J, Baker S, et al. Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2006;30(4): 315-21.
43. Haynes LF, Korte JE, Holmes BE, Gooden L, Matheson T, Feaster DJ, et al. HIV rapid testing in substance abuse treatment: implementation following a clinical trial. Eval Program Plann. 2011;34(4):399-406.
44. Bogart LM, Kral AH, Scott A, Anderson R, Flynn N, Gilbert ML, et al. Sexual risk among injection drug users recruited from syringe exchange programs in California. Sex Transm Dis. 2005;32(1):27-34.
45. Marshall BD, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Condom use among injection drug users accessing a supervised injecting facility. Sex Transm Infect. 2009;85(2):121-6.
46. Kidorf M, King VL, Pierce J, Kolodner K, Brooner RK. Benefits of concurrent syringe exchange and substance abuse treatment participation. J Subst Abuse Treat. 2011; 40(3):265-71.
47. Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Semaan S. Associations between herpes simplex virus type 2 and HCV with HIV among injecting drug users in New York City: the current importance of sexual transmission of HIV. Am J Public Health. 2011;101(7):1277-83.
48. Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Torian LV, et al. HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend. 2010;109(1-3)154-60.
49. Elovich R, Drucker E. On drug treatment and social control: Russian narcology's great leap backwards. Harm Reduct J. 2008;5:23.
50. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: national findings [Internet]. Rockville (MD): SAMHSA; [last updated 2008 Sep 4; cited 2011 Jul 20]. Available from: http://www.oas.samhsa.gov/nsduh/ 2k7nsduh/2k7Results.cfm#7.2
51. Tempalski B, Cleland CM, Pouget ER, Chatterjee S, Friedman SR. Persistence of low drug treatment coverage for injection drug users in large US metropolitan areas. Subst Abuse Treat Prev Policy. 2010;5:23.
52. Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009;301(2):183-90.
53. Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4(11):e7558.
54. Jürgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis. 2009; 9(1):57-66.
55. Larney S, Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Eur Addict Res. 2009;15(2):107-12.
56. Zarkin GA, Cowell AJ, Hicks KA, Mills MJ, Belenko S, Dunlap LJ, et al. Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model. Health Econ. Epub 2011 Apr 19.
57. Rich JD, Wakeman SE, Dickman SL. Medicine and the epidemic of incarceration in the United States. N Engl J Med. 2011;364(22):2081-3.
58. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-oftreatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6(9):1049-56.
59. Wood E, Werb D, Marshall BD, Montaner JS, Kerr T. The war on drugs: a devastating public-policy disaster. Lancet. 2009;373(9668): 989-90.
60. Centers for Disease Control and Prevention. Recommendations and guidelines: treatment [Internet]. Atlanta (GA): CDC; [last modified 2010 Dec 16; cited 2011 Jul 20]. Available from: http://www.cdc.gov/ hiv/resources/guidelines/ #treatment
61. Des Jarlais DC. Structural interventions to reduce HIV transmission among injecting drug users. AIDS. 2000;14(Suppl 1):S41-6.
62. Briggs D, Rhodes T, Marks D, Kimber J, Holloway G, Jones S. Injecting drug use and unstable housing: scope for structural interventions in harm reduction. Drugs: Educ Prev Policy. 2009;16(5): 436-50.
63. Kidder D, Wolitski RJ, Royal S, Aidala A, Courtenay-Quirk C, Holtgrave DR, et al. Access to housing as a structural intervention for homeless and unstably housed people living with HIV: rationale, methods, and implementation of the Housing and Health Study. AIDS Behav. 2007;11(6 Suppl):149-61.
64. Blankenship KM, Friedman SR, Dworkin S, Mantell JE. Structural interventions: concepts, challenges, and opportunities for research. J Urban Health. 2006;83(1):59-72.
65. Bini EJ, Kritz S, Brown LS Jr., Robinson J, Alderson D, Rotrosen J. Barriers to providing health services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis. 2011;30(2):98-109.
66. Schackman BR. Implementation science for the prevention and treatment of HIV/AIDS. J Acquir Immune Defic Syndr. 2011; 55(Suppl 1):S27-31.
67. Friedman SR, Cooper HL, Tempalski B, Keem M, Friedman R, Flom PL, et al. Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas. AIDS. 2006;20(1):93-9.
68. Schackman BR, Merrill JO, McCarty D, Levi J, Lubinski C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006;43(Suppl 4):S247-53.
69. Donoghoe MC, Verster A, Pervilhac C, Williams P. Setting targets for universal access to HIV prevention, treatment, and care for injecting drug users (IDUs): towards consensus and improved guidance. Int J Drug Policy. 2008;19(Suppl 1): S5-14.
70. Tkatchenko-Schmidt E, Renton A, Gevorgyan R, Davydenko L, Atun R. Prevention of HIV/AIDS among injecting drug users in Russia: opportunities and barriers to scaling-up of harm reduction programmes. Health Policy. 2008;85(2):162-71.
71. Aceijas C, Hickman M, Donoghoe MC, Burrows D, Stuikyte R. Access and coverage of needle and syringe programmes (NSP) in central and eastern Europe and central Asia. Addiction. 2007;102(8):1244-50.